Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...
A retrospective case series of nine hospitalized patients found adjunctive oral JAK inhibitors were associated with rapid ...
SUN-627 demonstrated favorable safety, tolerability, and pharmacokinetics for oral, once-daily dosing in healthy volunteers Achieved full central nervous system (CNS) penetration and >90% inhibition ...
CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results